UCLA researchers use “rapid autopsies” to identify lethal molecular alterations in relapsed metastatic melanoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In a translational study from UCLA Jonsson Comprehensive Cancer Center, researchers analyzed genetic changes in the organs of recently deceased patients to understand how metastatic cutaneous melanoma spreads in those who had initially benefited from precision therapies. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Roger Lo, professor of medicine, dermatology, and molecular and medical pharmacology and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, was awarded a $2 million grant from NIH to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.

Login